{
  "extraction_metadata": {
    "timestamp": "2025-09-10T11:21:26.800422",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 7,
    "total_picos": 46
  },
  "picos_by_country": {
    "PT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PT",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "objective response rate (ORR), duration of response (DoR), disease control rate, progression-free survival (PFS), overall survival (OS), event-free survival, time to progression, time to next treatment, duration of treatment, adverse events (graded by Common Terminology Criteria for Adverse Events v5), serious adverse events (Grade 3-4), discontinuation due to adverse events, mortality-related toxicity, health-related quality of life, time to deterioration of overall health status, time to deterioration of physical functioning, quality of life (measured by change from baseline to week 12), survival outcomes summarized using Kaplan-Meier estimates, tumor response and progression evaluated by RECIST v1.1 with independent central confirmation"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel + nintedanib",
          "Outcomes": "objective response rate (ORR), duration of response (DoR), disease control rate, progression-free survival (PFS), overall survival (OS), event-free survival, time to progression, time to next treatment, duration of treatment, adverse events (graded by Common Terminology Criteria for Adverse Events v5), serious adverse events (Grade 3-4), discontinuation due to adverse events, mortality-related toxicity, health-related quality of life, time to deterioration of overall health status, time to deterioration of physical functioning, quality of life (measured by change from baseline to week 12), survival outcomes summarized using Kaplan-Meier estimates, tumor response and progression evaluated by RECIST v1.1 with independent central confirmation"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "objective response rate (ORR), duration of response (DoR), disease control rate, progression-free survival (PFS), overall survival (OS), event-free survival, time to progression, time to next treatment, duration of treatment, adverse events (graded by Common Terminology Criteria for Adverse Events v5), serious adverse events (Grade 3-4), discontinuation due to adverse events, mortality-related toxicity, health-related quality of life, time to deterioration of overall health status, time to deterioration of physical functioning, quality of life (measured by change from baseline to week 12), survival outcomes summarized using Kaplan-Meier estimates, tumor response and progression evaluated by RECIST v1.1 with independent central confirmation"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab",
          "Outcomes": "objective response rate (ORR), duration of response (DoR), disease control rate, progression-free survival (PFS), overall survival (OS), event-free survival, time to progression, time to next treatment, duration of treatment, adverse events (graded by Common Terminology Criteria for Adverse Events v5), serious adverse events (Grade 3-4), discontinuation due to adverse events, mortality-related toxicity, health-related quality of life, time to deterioration of overall health status, time to deterioration of physical functioning, quality of life (measured by change from baseline to week 12), survival outcomes summarized using Kaplan-Meier estimates, tumor response and progression evaluated by RECIST v1.1 with independent central confirmation"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "objective response rate (ORR), duration of response (DoR), disease control rate, progression-free survival (PFS), overall survival (OS), event-free survival, time to progression, time to next treatment, duration of treatment, adverse events (graded by Common Terminology Criteria for Adverse Events v5), serious adverse events (Grade 3-4), discontinuation due to adverse events, mortality-related toxicity, health-related quality of life, time to deterioration of overall health status, time to deterioration of physical functioning, quality of life (measured by change from baseline to week 12), survival outcomes summarized using Kaplan-Meier estimates, tumor response and progression evaluated by RECIST v1.1 with independent central confirmation"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab",
          "Outcomes": "objective response rate (ORR), duration of response (DoR), disease control rate, progression-free survival (PFS), overall survival (OS), event-free survival, time to progression, time to next treatment, duration of treatment, adverse events (graded by Common Terminology Criteria for Adverse Events v5), serious adverse events (Grade 3-4), discontinuation due to adverse events, mortality-related toxicity, health-related quality of life, time to deterioration of overall health status, time to deterioration of physical functioning, quality of life (measured by change from baseline to week 12), survival outcomes summarized using Kaplan-Meier estimates, tumor response and progression evaluated by RECIST v1.1 with independent central confirmation"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "platinum doublet",
          "Outcomes": "objective response rate (ORR), duration of response (DoR), disease control rate, progression-free survival (PFS), overall survival (OS), event-free survival, time to progression, time to next treatment, duration of treatment, adverse events (graded by Common Terminology Criteria for Adverse Events v5), serious adverse events (Grade 3-4), discontinuation due to adverse events, mortality-related toxicity, health-related quality of life, time to deterioration of overall health status, time to deterioration of physical functioning, quality of life (measured by change from baseline to week 12), survival outcomes summarized using Kaplan-Meier estimates, tumor response and progression evaluated by RECIST v1.1 with independent central confirmation"
        },
        {
          "Population": "tumours expressing PD-L1 with a TPS >=1%",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "objective response rate (ORR), duration of response (DoR), disease control rate, progression-free survival (PFS), overall survival (OS), event-free survival, time to progression, time to next treatment, duration of treatment, adverse events (graded by Common Terminology Criteria for Adverse Events v5), serious adverse events (Grade 3-4), discontinuation due to adverse events, mortality-related toxicity, health-related quality of life, time to deterioration of overall health status, time to deterioration of physical functioning, quality of life (measured by change from baseline to week 12), survival outcomes summarized using Kaplan-Meier estimates, tumor response and progression evaluated by RECIST v1.1 with independent central confirmation"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 7744
    },
    "FR": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "Patients treated with immunotherapy monotherapy in the first line",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "chemotherapy based on platinum salts, such as in the 1st line: cisplatin-vinorelbine, cisplatine-citagembine, carboplatin-paclitaxel, cisplain-docetaxel, Cisplatin-pemetrexed (non-epidermoid only)",
          "Outcomes": "progression-free survival (PFS) as assessed by an independent, blinded review panel according to RECIST 1.1 criteria, progression-free survival (PFS) sensitivity analysis considering initiation of new anti-cancer therapy as a PFS event, objective response rate (ORR) as evaluated by an independent review committee and defined as the proportion of patients with complete or partial response according to RECIST 1.1, overall survival (OS) defined as time between randomization and date of death from any cause, duration of response (DoR) defined as time from first partial or complete response to first relapse or progression (RECIST 1.1) or death from any cause, disease control rate defined as the proportion of patients with complete response, partial response, or stable disease for at least 5 weeks, time to response defined as time from initiation of treatment to first complete or partial response, adverse events (including serious adverse events and serious undesirable effects), discontinuation due to adverse events, health-related quality of life (including adjustment for median survival in certain quality of life dimensions), tolerance profile"
        },
        {
          "Population": "patients treated with chemotherapeutic therapy + immunotherapies in the line 1",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "chemotherapists in the single line: pemetrexed, docetaxel (non-epidermoside only)",
          "Outcomes": "progression-free survival (PFS) as assessed by an independent, blinded review panel according to RECIST 1.1 criteria, progression-free survival (PFS) sensitivity analysis considering initiation of new anti-cancer therapy as a PFS event, objective response rate (ORR) as evaluated by an independent review committee and defined as the proportion of patients with complete or partial response according to RECIST 1.1, overall survival (OS) defined as time between randomization and date of death from any cause, duration of response (DoR) defined as time from first partial or complete response to first relapse or progression (RECIST 1.1) or death from any cause, disease control rate defined as the proportion of patients with complete response, partial response, or stable disease for at least 5 weeks, time to response defined as time from initiation of treatment to first complete or partial response, adverse events (including serious adverse events and serious undesirable effects), discontinuation due to adverse events, health-related quality of life (including adjustment for median survival in certain quality of life dimensions), tolerance profile"
        },
        {
          "Population": "patients receiving first line bi-chemotherapy, without immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "immunotherapeutic treatment: atezolizumab, nivolumab or pembrolizimab (if PD-L1 â‰¥ 1%)",
          "Outcomes": "progression-free survival (PFS) as assessed by an independent, blinded review panel according to RECIST 1.1 criteria, progression-free survival (PFS) sensitivity analysis considering initiation of new anti-cancer therapy as a PFS event, objective response rate (ORR) as evaluated by an independent review committee and defined as the proportion of patients with complete or partial response according to RECIST 1.1, overall survival (OS) defined as time between randomization and date of death from any cause, duration of response (DoR) defined as time from first partial or complete response to first relapse or progression (RECIST 1.1) or death from any cause, disease control rate defined as the proportion of patients with complete response, partial response, or stable disease for at least 5 weeks, time to response defined as time from initiation of treatment to first complete or partial response, adverse events (including serious adverse events and serious undesirable effects), discontinuation due to adverse events, health-related quality of life (including adjustment for median survival in certain quality of life dimensions), tolerance profile"
        },
        {
          "Population": "patients receiving first line bi-chemotherapy, without immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel, pemetrexed (non-epidermoid only)",
          "Outcomes": "progression-free survival (PFS) as assessed by an independent, blinded review panel according to RECIST 1.1 criteria, progression-free survival (PFS) sensitivity analysis considering initiation of new anti-cancer therapy as a PFS event, objective response rate (ORR) as evaluated by an independent review committee and defined as the proportion of patients with complete or partial response according to RECIST 1.1, overall survival (OS) defined as time between randomization and date of death from any cause, duration of response (DoR) defined as time from first partial or complete response to first relapse or progression (RECIST 1.1) or death from any cause, disease control rate defined as the proportion of patients with complete response, partial response, or stable disease for at least 5 weeks, time to response defined as time from initiation of treatment to first complete or partial response, adverse events (including serious adverse events and serious undesirable effects), discontinuation due to adverse events, health-related quality of life (including adjustment for median survival in certain quality of life dimensions), tolerance profile"
        },
        {
          "Population": "patients receiving first line bi-chemotherapy, without immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "paclitaxel + bevacizumab",
          "Outcomes": "progression-free survival (PFS) as assessed by an independent, blinded review panel according to RECIST 1.1 criteria, progression-free survival (PFS) sensitivity analysis considering initiation of new anti-cancer therapy as a PFS event, objective response rate (ORR) as evaluated by an independent review committee and defined as the proportion of patients with complete or partial response according to RECIST 1.1, overall survival (OS) defined as time between randomization and date of death from any cause, duration of response (DoR) defined as time from first partial or complete response to first relapse or progression (RECIST 1.1) or death from any cause, disease control rate defined as the proportion of patients with complete response, partial response, or stable disease for at least 5 weeks, time to response defined as time from initiation of treatment to first complete or partial response, adverse events (including serious adverse events and serious undesirable effects), discontinuation due to adverse events, health-related quality of life (including adjustment for median survival in certain quality of life dimensions), tolerance profile"
        },
        {
          "Population": "adult patients with advanced CBNPC, with KRAS G12C mutation, whose disease has progressed after at least one prior systemic treatment line",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "chemotherapy",
          "Outcomes": "progression-free survival (PFS) as assessed by an independent, blinded review panel according to RECIST 1.1 criteria, progression-free survival (PFS) sensitivity analysis considering initiation of new anti-cancer therapy as a PFS event, objective response rate (ORR) as evaluated by an independent review committee and defined as the proportion of patients with complete or partial response according to RECIST 1.1, overall survival (OS) defined as time between randomization and date of death from any cause, duration of response (DoR) defined as time from first partial or complete response to first relapse or progression (RECIST 1.1) or death from any cause, disease control rate defined as the proportion of patients with complete response, partial response, or stable disease for at least 5 weeks, time to response defined as time from initiation of treatment to first complete or partial response, adverse events (including serious adverse events and serious undesirable effects), discontinuation due to adverse events, health-related quality of life (including adjustment for median survival in certain quality of life dimensions), tolerance profile"
        },
        {
          "Population": "adult patients with advanced CBNPC, with KRAS G12C mutation, whose disease has progressed after at least one prior systemic treatment line",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "immunotherapy",
          "Outcomes": "progression-free survival (PFS) as assessed by an independent, blinded review panel according to RECIST 1.1 criteria, progression-free survival (PFS) sensitivity analysis considering initiation of new anti-cancer therapy as a PFS event, objective response rate (ORR) as evaluated by an independent review committee and defined as the proportion of patients with complete or partial response according to RECIST 1.1, overall survival (OS) defined as time between randomization and date of death from any cause, duration of response (DoR) defined as time from first partial or complete response to first relapse or progression (RECIST 1.1) or death from any cause, disease control rate defined as the proportion of patients with complete response, partial response, or stable disease for at least 5 weeks, time to response defined as time from initiation of treatment to first complete or partial response, adverse events (including serious adverse events and serious undesirable effects), discontinuation due to adverse events, health-related quality of life (including adjustment for median survival in certain quality of life dimensions), tolerance profile"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 7156
    },
    "PO": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PO",
      "PICOs": [
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sotorasib",
          "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), overall survival (OS), health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires), adverse events (including very common undesirable effects such as anaemia, headache, cough, shortness of breath, diarrhoea, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase activity, increased alanine aminotransferase activity), treatment-related adverse events, treatment-related adverse reactions of grade 3 or higher, treatment-associated adverse experiences leading to discontinuation of therapy, dose modification-related adverse drug reactions, treatment-associated adverse events resulting in death, cost-effectiveness (incremental cost-effectiveness ratio, ICER), budget impact analysis, resource use estimates"
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "adagrasib",
          "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), overall survival (OS), health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires), adverse events (including very common undesirable effects such as anaemia, headache, cough, shortness of breath, diarrhoea, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase activity, increased alanine aminotransferase activity), treatment-related adverse events, treatment-related adverse reactions of grade 3 or higher, treatment-associated adverse experiences leading to discontinuation of therapy, dose modification-related adverse drug reactions, treatment-associated adverse events resulting in death, cost-effectiveness (incremental cost-effectiveness ratio, ICER), budget impact analysis, resource use estimates"
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "chemotherapy (docetaxel or pemetrexed)",
          "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), overall survival (OS), health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires), adverse events (including very common undesirable effects such as anaemia, headache, cough, shortness of breath, diarrhoea, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase activity, increased alanine aminotransferase activity), treatment-related adverse events, treatment-related adverse reactions of grade 3 or higher, treatment-associated adverse experiences leading to discontinuation of therapy, dose modification-related adverse drug reactions, treatment-associated adverse events resulting in death, cost-effectiveness (incremental cost-effectiveness ratio, ICER), budget impact analysis, resource use estimates"
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel in combination with nintedanib",
          "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), overall survival (OS), health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires), adverse events (including very common undesirable effects such as anaemia, headache, cough, shortness of breath, diarrhoea, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase activity, increased alanine aminotransferase activity), treatment-related adverse events, treatment-related adverse reactions of grade 3 or higher, treatment-associated adverse experiences leading to discontinuation of therapy, dose modification-related adverse drug reactions, treatment-associated adverse events resulting in death, cost-effectiveness (incremental cost-effectiveness ratio, ICER), budget impact analysis, resource use estimates"
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "EGFR inhibitors in patients who have not received these medicines in the first line",
          "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), overall survival (OS), health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires), adverse events (including very common undesirable effects such as anaemia, headache, cough, shortness of breath, diarrhoea, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase activity, increased alanine aminotransferase activity), treatment-related adverse events, treatment-related adverse reactions of grade 3 or higher, treatment-associated adverse experiences leading to discontinuation of therapy, dose modification-related adverse drug reactions, treatment-associated adverse events resulting in death, cost-effectiveness (incremental cost-effectiveness ratio, ICER), budget impact analysis, resource use estimates"
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "osymertinib in patients previously treated with first or second generation EGFR blockers",
          "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), overall survival (OS), health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires), adverse events (including very common undesirable effects such as anaemia, headache, cough, shortness of breath, diarrhoea, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase activity, increased alanine aminotransferase activity), treatment-related adverse events, treatment-related adverse reactions of grade 3 or higher, treatment-associated adverse experiences leading to discontinuation of therapy, dose modification-related adverse drug reactions, treatment-associated adverse events resulting in death, cost-effectiveness (incremental cost-effectiveness ratio, ICER), budget impact analysis, resource use estimates"
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "ALK inhibitors if ALK gene rearrangement",
          "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), overall survival (OS), health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires), adverse events (including very common undesirable effects such as anaemia, headache, cough, shortness of breath, diarrhoea, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase activity, increased alanine aminotransferase activity), treatment-related adverse events, treatment-related adverse reactions of grade 3 or higher, treatment-associated adverse experiences leading to discontinuation of therapy, dose modification-related adverse drug reactions, treatment-associated adverse events resulting in death, cost-effectiveness (incremental cost-effectiveness ratio, ICER), budget impact analysis, resource use estimates"
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab",
          "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), overall survival (OS), health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires), adverse events (including very common undesirable effects such as anaemia, headache, cough, shortness of breath, diarrhoea, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase activity, increased alanine aminotransferase activity), treatment-related adverse events, treatment-related adverse reactions of grade 3 or higher, treatment-associated adverse experiences leading to discontinuation of therapy, dose modification-related adverse drug reactions, treatment-associated adverse events resulting in death, cost-effectiveness (incremental cost-effectiveness ratio, ICER), budget impact analysis, resource use estimates"
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab",
          "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), overall survival (OS), health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires), adverse events (including very common undesirable effects such as anaemia, headache, cough, shortness of breath, diarrhoea, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase activity, increased alanine aminotransferase activity), treatment-related adverse events, treatment-related adverse reactions of grade 3 or higher, treatment-associated adverse experiences leading to discontinuation of therapy, dose modification-related adverse drug reactions, treatment-associated adverse events resulting in death, cost-effectiveness (incremental cost-effectiveness ratio, ICER), budget impact analysis, resource use estimates"
        },
        {
          "Population": "sotorasib (SOT) was compared with docetaxel (DOC), nintedanib in combination with docetexel (NIN+DOC) and pemetrexed (XPM)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), overall survival (OS), health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires), adverse events (including very common undesirable effects such as anaemia, headache, cough, shortness of breath, diarrhoea, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase activity, increased alanine aminotransferase activity), treatment-related adverse events, treatment-related adverse reactions of grade 3 or higher, treatment-associated adverse experiences leading to discontinuation of therapy, dose modification-related adverse drug reactions, treatment-associated adverse events resulting in death, cost-effectiveness (incremental cost-effectiveness ratio, ICER), budget impact analysis, resource use estimates"
        },
        {
          "Population": "sotorasib (SOT) was compared with docetaxel (DOC), nintedanib in combination with docetexel (NIN+DOC) and pemetrexed (XPM)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nintedanib in combination with docetaxel",
          "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), overall survival (OS), health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires), adverse events (including very common undesirable effects such as anaemia, headache, cough, shortness of breath, diarrhoea, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase activity, increased alanine aminotransferase activity), treatment-related adverse events, treatment-related adverse reactions of grade 3 or higher, treatment-associated adverse experiences leading to discontinuation of therapy, dose modification-related adverse drug reactions, treatment-associated adverse events resulting in death, cost-effectiveness (incremental cost-effectiveness ratio, ICER), budget impact analysis, resource use estimates"
        },
        {
          "Population": "sotorasib (SOT) was compared with docetaxel (DOC), nintedanib in combination with docetexel (NIN+DOC) and pemetrexed (XPM)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), overall survival (OS), health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires), adverse events (including very common undesirable effects such as anaemia, headache, cough, shortness of breath, diarrhoea, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase activity, increased alanine aminotransferase activity), treatment-related adverse events, treatment-related adverse reactions of grade 3 or higher, treatment-associated adverse experiences leading to discontinuation of therapy, dose modification-related adverse drug reactions, treatment-associated adverse events resulting in death, cost-effectiveness (incremental cost-effectiveness ratio, ICER), budget impact analysis, resource use estimates"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with a KRas g12c mutation who have experienced disease progression after at least one line of previous use",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), overall survival (OS), health-related quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires), adverse events (including very common undesirable effects such as anaemia, headache, cough, shortness of breath, diarrhoea, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase activity, increased alanine aminotransferase activity), treatment-related adverse events, treatment-related adverse reactions of grade 3 or higher, treatment-associated adverse experiences leading to discontinuation of therapy, dose modification-related adverse drug reactions, treatment-associated adverse events resulting in death, cost-effectiveness (incremental cost-effectiveness ratio, ICER), budget impact analysis, resource use estimates"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 7003
    },
    "SE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "adult patients with advanced NSCLC with a KRAS G12C mutation, following progression from at least one prior line of systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel monotherapy",
          "Outcomes": "progression-free survival (PFS), overall survival (OS), health-related quality of life (measured by time to death), quality-adjusted life years (QALYs), cost per QALY achieved, safety, resource use, cost-effectiveness"
        },
        {
          "Population": "patients with advanced non-small cell lung cancer (NSCLC) with the KRAS G12C mutation who have progressed after at least one prior line of systemic therapy and have been treated with docetaxel or who are not medically suitable for treatment with Docetaxel",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression-free survival (PFS), overall survival (OS), health-related quality of life (measured by time to death), quality-adjusted life years (QALYs), cost per QALY achieved, safety, resource use, cost-effectiveness"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 6713
    },
    "EN": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EN",
      "PICOs": [
        {
          "Population": "previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "overall survival (OS), progression-free survival (PFS), health-related quality of life, objective response rate (RECIST 1.1), adverse events, discontinuation due to adverse events, treatment-related disutility for intravenous administration, utilities derived through a visual analogue scale in the progression-free health state, cost-effectiveness estimates"
        },
        {
          "Population": "previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel plus nintedanib",
          "Outcomes": "overall survival (OS), progression-free survival (PFS), health-related quality of life, objective response rate (RECIST 1.1), adverse events, discontinuation due to adverse events, treatment-related disutility for intravenous administration, utilities derived through a visual analogue scale in the progression-free health state, cost-effectiveness estimates"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 6324
    },
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "Adults with locally advanced and unresectable or metastatic NSCLC with molecularly diagnosed KRAS G12C mutation. Patients had to have disease progression during or after at least 1 prior systemic therapy for advanced or unresectable stage of the disease. Prior therapy should include combined or sequential platinum-containing combination chemotherapy and an anti-PD-1/PD-L1.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), endpoints on symptomatology and health status, health-related quality of life (measured using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), side effects (adverse events)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), endpoints on symptomatology and health status, health-related quality of life (measured using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), side effects (adverse events)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), endpoints on symptomatology and health status, health-related quality of life (measured using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), side effects (adverse events)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), endpoints on symptomatology and health status, health-related quality of life (measured using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), side effects (adverse events)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), endpoints on symptomatology and health status, health-related quality of life (measured using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), side effects (adverse events)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), endpoints on symptomatology and health status, health-related quality of life (measured using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), side effects (adverse events)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel in combination with nintedanib",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), endpoints on symptomatology and health status, health-related quality of life (measured using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), side effects (adverse events)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy and for whom a therapy other than docetaxel is the appropriate patient-individual therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), endpoints on symptomatology and health status, health-related quality of life (measured using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), side effects (adverse events)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy and for whom a therapy other than docetaxel is the appropriate patient-individual therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "afatinib",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), endpoints on symptomatology and health status, health-related quality of life (measured using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), side effects (adverse events)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy and for whom a therapy other than docetaxel is the appropriate patient-individual therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "erlotinib",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), endpoints on symptomatology and health status, health-related quality of life (measured using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), side effects (adverse events)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy and for whom a therapy other than docetaxel is the appropriate patient-individual therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel in combination with ramucirumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), endpoints on symptomatology and health status, health-related quality of life (measured using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), side effects (adverse events)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy and for whom a therapy other than docetaxel is the appropriate patient-individual therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel in combination with nintedanib",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), endpoints on symptomatology and health status, health-related quality of life (measured using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), side effects (adverse events)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy and for whom a therapy other than docetaxel is the appropriate patient-individual therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "vinorelbine",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), endpoints on symptomatology and health status, health-related quality of life (measured using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), side effects (adverse events)"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 7107
    },
    "DK": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel monotherapy",
          "Outcomes": "overall survival (OS), progression-free survival (PFS), event-free survival, time to progression (TTP), time to next treatment (TTNT), progression after next line of therapy (PFS2), objective response rate (ORR), disease control rate, time to response, duration of response, adverse events (AEs, including grade â‰¥3 and treatment discontinuation due to AEs, measured by CTCAE v4.03 or v5.0), health-related quality of life (HRQoL), patient-reported outcomes (PROs, including EORTC QLQ), quality-adjusted life years (QALYs), resource use estimates, cost-effectiveness (incremental cost-effectiveness ratio, ICER)"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 7749
    }
  }
}